September 30, 2026 04:25 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Israel-bound flight lands in Saudi Arabia as pilots fight in cockpit, stabbing triggers hijack scare mid-air | Vimal ad row: SRK, Ajay Devgn, Tiger Shroff respond to FDA notices, says Tukaram Mundhe | Vijay’s TVK expands to Bengal? Party breaks silence on Purba Bardhaman office | ‘This guy is a monster’: Trump’s hilarious praise for Sundar Pichai, Google CEO’s witty reply | Gyanesh Kumar row exposes INDIA bloc rift: DMK, AAP skip meet, Akhilesh sends representative | SIR row: Supreme Court to hear plea against CEC Gyanesh Kumar next week | Sambhal violence case: SC quashes key accused Mulla Afroz's NSA detention, slaps Rs 10 lakh cost on UP govt | Nandigram bypoll twist: Calcutta HC grants interim bail to Congress candidate Milan Pradhan till Oct 21 | Myanmar military airstrike horror: 49 killed, 58 injured as bombs hit crowded Rakhine market | Britain reopens refugee routes for Afghans, Palestinians as immigration and integration battle intensifies
Johnson Baby Powder
Image Credit: wikipedia.org

Maharashtra FDA cancels Johnson & Johnson baby powder licence

| @indiablooms | Sep 18, 2022, at 05:06 am

Mumbai: The Maharashtra FDA has cancelled the baby talcum powder manufacturing licence of Johnson & Johnson, Mulund, after the department found it "Not Of Standard Quality".

The FDA said that the licence was cancelled after samples of the Johnson’s Baby Powder collected from Nashik and Pune failed quality checks and ordered the company to recall all its stocks from the markets.

These samples were declared by the FDA as ‘Not Of Standard Quality’ after they failed to comply with IS5339:2009 (Second Revision Amendment No. 3) Specification for Skin Powder for infants in the test pH.

In a statement, the FDA said: “The product Johnsons Baby Powder is popularly used in newborn babies. The sample declared 'Not of Standard' in pH and the use of the product may affect the health of the skin of the newborn babies.”

The firm "didn't accept the report" and challenged it in court for sending it to the Central Drugs Laboratory, the FDA said, according to media reports.

(With UNI inputs)

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.